Illkirch
Other
Syndivia
is a biopharmaceutical company that develops and commercializes novel therapies for the treatment of cancer... Read moreSyndivia
is a biopharmaceutical company that develops and commercializes novel therapies for the treatment of cancer... Read moreNews
Oct 29, 2025
Pulse2.0
Syndivia: GSK Buys Exclusive Rights To Syndivia's Antibody-Drug Conjugate For Prostate Cancer
Oct 28, 2025
BioCentury
Syndivia: GSK adds therapies for COPD, prostate cancer: Deals Report
Nov 16, 2023
Yahoo
Syndivia: Renowned Nobel Laureate Jean-Marie Lehn Appointed Chairman of Syndivia's Scientific Advisory Board
Mar 11, 2020
FinSMEs
Syndivia: Syndivia Raises €2m in Financing
Jan 28, 2020
FirstWord Pharma
Syndivia: Syndivia In-Licenses DARx Technology for 1-to-1 Linkage of Antibodies and Payloads for Preparation of New Classes of Biologics
Jan 17, 2020
pipelinereview
Syndivia: Syndivia In-Licenses Novel Antibody Against Tumor-Specific Form of CD146 From SATT Sud-Est
Dec 10, 2019
PR Newswire
Press Release: Syndivia : Syndivia Raises €1M Investment to Advance Its Tumour Microenvironment Drug Delivery Platform
Dec 10, 2019
firstwordpharma
Syndivia: Syndivia Raises €1M Investment to Advance Its Tumour Microenvironment Drug Delivery Platform
